Business context and reporting period
Filing identity: The supplied filing is Zafgen, Inc.’s Form 10-Q for the quarter ended June 30, 2015, filed August 14, 2015. It does not identify Larimar Therapeutics, Inc.; investors should verify the issuer before relying on this summary.
Zafgen was a clinical-stage biopharmaceutical company developing beloranib, a MetAP2 inhibitor, for obesity-related indications, including Prader-Willi syndrome (PWS), hypothalamic injury-associated obesity, and severe obesity. It was also developing ZGN-839 and other MetAP2 inhibitors. The company had no approved products and had not generated product revenue.
Financial results and liquidity
Amounts below are in millions of U.S. dollars except per-share data. The filing presents unaudited results.
| Metric | Q2 2015 | Q2 2014 | Six months 2015 | Six months 2014 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $12.526 | $4.695 | $22.741 | $7.970 |
| General and administrative | $5.084 | $1.291 | $8.109 | $2.537 |
| Total operating expenses | $17.610 | $5.986 | $30.850 | $10.507 |
| Net loss | $(17.756) | $(6.400) | $(31.228) | $(10.858) |
| Net loss per share | $(0.66) | $(2.96) | $(1.19) | $(7.51) |
Profitability and operating margins are not meaningful because the company had no revenue. For the six months ended June 30, operating cash use was $25.474 million, investing cash use was $79.065 million, and financing provided $130.009 million, principally from a January follow-on offering. Cash and cash equivalents were $83.573 million; marketable securities were $136.547 million. Together these totaled approximately $220.1 million, versus $115.5 million at December 31, 2014.
At June 30, total assets were $222.602 million, total liabilities $16.409 million, and stockholders’ equity $206.193 million. Credit-facility principal outstanding was $7.5 million; the debt carried an approximately 14% effective annual interest rate. Current notes payable were $2.820 million on the balance sheet.
Material changes versus the prior comparable period
- Q2 operating expenses rose $11.624 million year over year; six-month expenses rose $20.343 million. Management attributed the increase mainly to beloranib clinical-trial activity, greater investment in early-stage programs, hiring, and public-company and commercial-readiness costs.
- Beloranib clinical-trial R&D expense increased $3.746 million in Q2 and $6.717 million in the first half. ZGN-839 and second-generation inhibitor costs also increased as the company expanded early-stage work.
- G&A increased $3.793 million in Q2 and $5.572 million in the first half, including higher professional fees, personnel and stock-based compensation.
- Cash and marketable securities increased substantially following the $130.044 million net proceeds from the January 2015 follow-on offering. Common shares outstanding increased from 22.879 million at year-end 2014 to 27.118 million at June 30, 2015.
Outlook, risks and unusual items
Management expected existing cash and marketable securities to fund operating and capital needs for at least 18 months from June 30, 2015, while cautioning that assumptions could prove wrong and funds might be used sooner. It expected rising R&D spending and operating losses and stated that additional financing would be needed to support continuing operations. The filing provides no conventional revenue or earnings guidance.
The company reported that its U.S. Phase 3 PWS trial had completed enrollment of 108 patients in May 2015 and planned to start a second, primarily European PWS Phase 3 trial in Q3 2015. Its Phase 2b severe-obesity trial in patients with type 2 diabetes was more than 95% enrolled, with enrollment expected to finish in August 2015; an interim analysis was expected in late 2015 or early 2016. These are management plans and expectations, not assured outcomes.
Key risks included dependence on beloranib, uncertain clinical and regulatory outcomes, possible additional studies, safety and trial-enrollment risks, reliance on contract manufacturers and research organizations, uncertain commercialization and reimbursement, competition, patent and licensing exposure, and future financing needs. The filing noted adverse events in completed Phase 2 trials including dizziness, sleep disturbances, nausea and vomiting; the company stated no serious adverse events had been attributed to beloranib in those completed trials. Beloranib-related license agreements could require up to $12.25 million in pre-commercial milestones and up to $12.5 million in commercialization milestones, plus royalties if products are sold. The company reported no legal proceedings as of the filing date and no off-balance-sheet arrangements.
Most important facts for investors to verify
- Confirm the issuer: the supplied document is a Zafgen, Inc. filing, not a Larimar Therapeutics filing.
- Check the subsequent status and results of the PWS Phase 3 trials and the severe-obesity Phase 2b trial, including safety disclosures and regulatory requirements.
- Assess whether the stated 18-month cash runway assumptions remain valid against the reported $25.474 million first-half operating cash use and planned trial spending.
- Review the terms, repayment schedule and effective cost of the $7.5 million credit facility, along with the potential license milestones and royalties.
- Confirm whether additional financing, dilution, or changes in development plans became necessary after the reporting date.